Supplementary Material

Anosognosia is associated with increased prevalence and faster development of neuropsychiatric symptoms in mild cognitive impairment

Wang, S.1, Mimmack, K.1, Cacciamani, F.1,2,5,6, Elnemais, M.3,4, Munro, C.1,3,4, Gatchel, J.4,7,8, Marshall, G.1,3,4, Gagliardi, G. †1,3,4, Vannini, P. †\*1,3,4, for the Alzheimer’s Disease Neuroimaging Initiative

†These authors share senior authorship.

1Department of Neurology, Massachusetts General Hospital, Boston, MA, USA

2Bordeaux Population Health Center, University of Bordeaux, Inserm, Bordeaux, France

3Department of Neurology,Brigham and Women’s Hospital, Boston, MA, USA

4Harvard Medical School, Boston, MA, USA

5Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, CNRS, Inria, Inserm, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France

6Qarinel SAS, Paris, France

7Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA

8Division of Geriatric Psychiatry, McLean Hospital, Belmont, MA, USA

**\* Correspondence:**Patrizia Vannini  
patrizia@bwh.harvard.edu

# Supplementary Method

## *CSF Ptau*

CSF pTau data (UPENNBIOMK10\_07\_29\_19.csv) were downloaded from ADNI, using the analyses performed by the University of Pennsylvania ADNI Biomarker core laboratory. These CSF values were based on the Roche Elecsys and cobas e 601 immunoassay analyzer system. Among the 237 participants in the selected sample, 215 presented available CSF-PTAU measures (37 in the Anosognosia group and 178 in the Non-Anosognosia group).

# Supplementary Tables


**Supplementary Table 1.** Cox regression model outputs comparing the onset of NPS over time for participants with and without stable anosognosia. Covariates include those in the original analysis as well as amyloidosis. P-values are corrected for multiple comparisons using the Bonferroni method.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| NPS | Age (Baseline) | Sex (M) | Education (years) | Baseline MMSE | Amyloidosis | Group (**Anosognosia**) |
| Delusions |  |  |  |  |  |  |
| log(HR) | -0.02 | -0.54 | 0.07 | -0.18 | 3.70 | 1.00 |
| 95% CI | -0.09, 0.04 | -1.30, 0.23 | -0.08, 0.22 | -0.46, 0.10 | 2.10, 5.30 | 0.25, 1.80 |
| p-value | 1.000 | 1.000 | 1.000 | 1.000 | <0.001 | 0.117 |
| Hallucinations |  |  |  |  |  |  |
| log(HR) | -0.06 | -0.71 | -0.05 | 0.06 | 3.10 | 1.70 |
| 95% CI | -0.15, 0.03 | -1.80, 0.37 | -0.26, 0.16 | -0.40, 0.52 | 0.84, 5.40 | 0.57, 2.80 |
| p-value | 1.000 | 1.000 | 1.000 | 1.000 | 0.091 | 0.037 |
| Agitation / Aggression |  |  |  |  |  |  |
| log(HR) | -0.01 | 0.60 | 0.00 | -0.11 | 1.30 | 0.65 |
| 95% CI | -0.03, 0.01 | 0.26, 0.95 | -0.05, 0.05 | -0.21, -0.01 | 0.65, 1.90 | 0.33, 0.98 |
| p-value | 1.000 | 0.006 | 1.000 | 0.334 | <0.001 | <0.001 |
| Depression / Dysphoria |  |  |  |  |  |  |
| log(HR) | 0.01 | -0.11 | 0.02 | -0.03 | 0.61 | 0.26 |
| 95% CI | -0.01, 0.03 | -0.41, 0.18 | -0.03, 0.07 | -0.12, 0.07 | -0.02, 1.20 | -0.09, 0.61 |
| p-value | 1.000 | 1.000 | 1.000 | 1.000 | 0.716 | 1.000 |
| Anxiety |  |  |  |  |  |  |
| log(HR) | -0.01 | -0.13 | 0.03 | -0.18 | 0.91 | -0.15 |
| 95% CI | -0.03, 0.01 | -0.46, 0.20 | -0.03, 0.09 | -0.28, -0.08 | 0.21, 1.60 | -0.61, 0.30 |
| p-value | 1.000 | 1.000 | 1.000 | 0.004 | 0.129 | 1.000 |
| Elation / Euphoria |  |  |  |  |  |  |
| log(HR) | -0.03 | 1.80 | -0.15 | 0.43 | 0.00 | 0.78 |
| 95% CI | -0.08, 0.02 | 0.76, 2.90 | -0.27, -0.03 | 0.07, 0.79 | -1.70, 1.70 | 0.04, 1.50 |
| p-value | 1.000 | 0.010 | 0.165 | 0.241 | 1.000 | 0.472 |
| Apathy / Indifference |  |  |  |  |  |  |
| log(HR) | 0.02 | -0.24 | 0.03 | -0.18 | 1.40 | 0.99 |
| 95% CI | 0.00, 0.04 | -0.55, 0.06 | -0.02, 0.09 | -0.27, -0.09 | 0.76, 2.10 | 0.68, 1.30 |
| p-value | 0.866 | 1.000 | 1.000 | <0.001 | <0.001 | <0.001 |
| Disinhibition |  |  |  |  |  |  |
| log(HR) | -0.01 | 0.33 | -0.01 | 0.01 | 1.40 | 0.82 |
| 95% CI | -0.04, 0.02 | -0.07, 0.72 | -0.07, 0.06 | -0.12, 0.14 | 0.66, 2.20 | 0.44, 1.20 |
| p-value | 1.000 | 1.000 | 1.000 | 1.000 | 0.004 | <0.001 |
| Irritability / Lability |  |  |  |  |  |  |
| log(HR) | -0.01 | 0.61 | 0.01 | -0.10 | 0.91 | 0.60 |
| 95% CI | -0.02, 0.01 | 0.32, 0.89 | -0.03, 0.06 | -0.18, -0.02 | 0.31, 1.50 | 0.33, 0.88 |
| p-value | 1.000 | <0.001 | 1.000 | 0.210 | 0.034 | <0.001 |
| Aberrant Motor Behavior |  |  |  |  |  |  |
| log(HR) | 0.02 | -0.04 | -0.06 | 0.13 | 3.0 | 0.74 |
| 95% CI | -0.02, 0.06 | -0.61, 0.53 | -0.16, 0.05 | -0.10, 0.35 | 1.90, 4.10 | 0.13, 1.30 |
| p-value | 1.000 | 1.000 | 1.000 | 1.000 | <0.001 | 0.205 |
| Sleep Disorders |  |  |  |  |  |  |
| log(HR) | -0.02 | 0.43 | 0.03 | -0.10 | 0.30 | -0.10 |
| 95% CI | -0.04, 0.00 | 0.12, 0.75 | -0.02, 0.08 | -0.19, -0.01 | -0.39, 0.98 | -0.48, 0.28 |
| p-value | 1.000 | 0.087 | 1.000 | 0.447 | 1.000 | 1.000 |
| Appetite and Eating Disorders |  |  |  |  |  |  |
| log(HR) | 0.01 | -0.48 | 0.07 | -0.17 | 1.30 | 0.11 |
| 95% CI | -0.01, 0.03 | -0.83, -0.13 | 0.00, 0.13 | -0.28, -0.07 | 0.55, 2.00 | -0.33, 0.54 |
| p-value | 1.000 | 0.089 | 0.529 | 0.015 | 0.007 | 1.000 |

**Supplementary Table 2.** Cox regression model outputs comparing the onset of NPS over time for participants with and without stable anosognosia. Covariates include those in the original analysis as well as amyloidosis and CSF pTau. P-values are corrected for multiple comparisons using the Bonferroni method.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| NPS | Age (Baseline) | Sex (M) | Education (years) | Baseline MMSE | Amyloidosis | CSF pTau | Group (Anosognosia) |
| Delusions |  |  |  |  |  |  |  |
| log(HR) | -0.07 | -1.10 | 0.13 | -0.16 | 4.30 | -0.01 | 1.00 |
| 95% CI | -0.14, 0.00 | -1.90, -0.16 | -0.04, 0.29 | -0.48, 0.17 | 2.40, 6.10 | -0.03, 0.01 | 0.18, 1.90 |
| p-value | 0.750 | 0.248 | 1.000 | 1.000 | <0.001 | 1.000 | 0.211 |
| Hallucinations |  |  |  |  |  |  |  |
| log(HR) | -0.17 | -1.50 | 0.04 | 0.43 | 5.40 | -0.03 | 2.50 |
| 95% CI | -0.29, -0.05 | -2.80, -0.17 | -0.20, 0.29 | -0.34, 1.20 | 2.30, 8.60 | -0.07, 0.01 | 0.93, 4.00 |
| p-value | 0.081 | 0.316 | 1.000 | 1.000 | 0.008 | 1.000 | 0.020 |
| Agitation / Aggression |  |  |  |  |  |  |  |
| log(HR) | 0.00 | 0.48 | -0.02 | -0.09 | 1.40 | 0.00 | 0.64 |
| 95% CI | -0.02, 0.02 | 0.12, 0.83 | -0.08, 0.04 | -0.20, 0.01 | 0.65, 2.10 | 0.00, 0.01 | 0.30, 0.97 |
| p-value | 1.000 | 0.103 | 1.000 | 0.981 | 0.002 | 1.000 | 0.002 |
| Depression / Dysphoria |  |  |  |  |  |  |  |
| log(HR) | 0.00 | -0.29 | 0.02 | 0.00 | 0.62 | 0.00 | 0.28 |
| 95% CI | -0.02, 0.02 | -0.61, 0.02 | -0.03, 0.08 | -0.11, 0.10 | -0.13, 1.40 | 0.00, 0.01 | -0.08, 0.63 |
| p-value | 1.000 | 0.794 | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 |
| Anxiety |  |  |  |  |  |  |  |
| log(HR) | -0.01 | -0.11 | 0.03 | -0.18 | 0.80 | 0.00 | -0.19 |
| 95% CI | -0.04, 0.01 | -0.47, 0.25 | -0.03, 0.09 | -0.29, -0.08 | -0.01, 1.60 | -0.01, 0.01 | -0.65, 0.28 |
| p-value | 1.000 | 1.000 | 1.000 | 0.011 | 0.635 | 1.000 | 1.000 |
| Elation / Euphoria |  |  |  |  |  |  |  |
| log(HR) | -0.05 | 1.40 | -0.13 | 0.32 | 0.46 | -0.01 | 0.68 |
| 95% CI | -0.10, 0.01 | 0.33, 2.50 | -0.26, 0.00 | -0.07, 0.71 | -1.50, 2.50 | -0.03, 0.01 | -0.11, 1.50 |
| p-value | 1.000 | 0.128 | 0.624 | 1.000 | 1.000 | 1.000 | 1.000 |
| Apathy / Indifference |  |  |  |  |  |  |  |
| log(HR) | 0.02 | -0.34 | 0.04 | -0.19 | 1.60 | 0.00 | 0.92 |
| 95% CI | -0.01, 0.04 | -0.66, -0.02 | -0.01, 0.10 | -0.29, -0.09 | 0.82, 2.40 | -0.01, 0.01 | 0.60, 1.20 |
| p-value | 1.000 | 0.447 | 1.000 | 0.002 | <0.001 | 1.000 | <0.001 |
| Disinhibition |  |  |  |  |  |  |  |
| log(HR) | -0.02 | 0.15 | 0.00 | -0.01 | 1.70 | -0.01 | 0.71 |
| 95% CI | -0.05, 0.01 | -0.27, 0.56 | -0.07, 0.06 | -0.15, 0.13 | 0.84, 2.50 | -0.02, 0.00 | 0.32, 1.10 |
| p-value | 1.000 | 1.000 | 1.000 | 1.000 | <0.001 | 0.552 | 0.004 |
| Irritability / Lability |  |  |  |  |  |  |  |
| log(HR) | 0.00 | 0.47 | 0.01 | -0.08 | 0.89 | 0.00 | 0.57 |
| 95% CI | -0.02, 0.01 | 0.18, 0.77 | -0.04, 0.06 | -0.17, 0.00 | 0.21, 1.60 | -0.01, 0.01 | 0.28, 0.85 |
| p-value | 1.000 | 0.022 | 1.000 | 0.726 | 0.128 | 1.000 | <0.001 |
| Aberrant Motor Behavior |  |  |  |  |  |  |  |
| log(HR) | 0.03 | -0.12 | -0.01 | 0.09 | 2.30 | 0.01 | 0.74 |
| 95% CI | -0.02, 0.07 | -0.75, 0.50 | -0.12, 0.10 | -0.13, 0.32 | 1.00, 3.60 | 0.00, 0.02 | 0.12, 1.40 |
| p-value | 1.000 | 1.000 | 1.000 | 1.000 | 0.005 | 0.595 | 0.243 |
| Sleep Disorders |  |  |  |  |  |  |  |
| log(HR) | -0.02 | 0.29 | 0.02 | -0.10 | 0.35 | 0.00 | -0.12 |
| 95% CI | -0.04, 0.00 | -0.04, 0.63 | -0.03, 0.08 | -0.20, -0.01 | -0.42, 1.10 | -0.01, 0.01 | -0.51, 0.26 |
| p-value | 1.000 | 0.990 | 1.000 | 0.466 | 1.000 | 1.000 | 1.000 |
| Appetite and Eating Disorders |  |  |  |  |  |  |  |
| log(HR) | 0.02 | -0.47 | 0.06 | -0.16 | 1.10 | 0.00 | 0.07 |
| 95% CI | -0.01, 0.04 | -0.83, -0.10 | -0.01, 0.13 | -0.27, -0.04 | 0.29, 2.00 | 0.00, 0.01 | -0.37, 0.51 |
| p-value | 1.000 | 0.152 | 0.863 | 0.078 | 0.098 | 1.000 | 1.000 |

# Supplementary Figure



**Supplementary Figure 1.** Cox regression model outputs comparing the onset of NPS over time for participants with and without stable anosognosia. The orange line indicates participants with anosognosia, and the blue line indicates participants without anosognosia.